FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Appelbaum

Research Profile

Procedures

Microbial Sensitivity Tests

Chemicals & Drugs

Living Beings

Physiology

Co-author Network

Publications

TOP 3
Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
Pamela McGhee; Catherine Clark; Kim Credito; Linda Beachel; Glenn A Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.
Glenn A Pankuch; Gengrong Lin; Aya Kubo; Eliana S Armstrong; Peter C Appelbaum; Klaudia Kosowska-Shick
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Appelbaum (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
Antimicrobial agents and chemotherapy 2011;55(5):2344-51.
2011: Pamela McGhee; Catherine Clark; Kim Credito; Linda Beachel; Glenn A Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.
Antimicrobial agents and chemotherapy 2011;55(5):2417-9.
2011: Glenn A Pankuch; Gengrong Lin; Aya Kubo; Eliana S Armstrong; Peter C Appelbaum; Klaudia Kosowska-Shick
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 2011;55(5):2463-5.
2011: Glenn A Pankuch; Gengrong Lin; Catherine Clark; Peter C Appelbaum
Time-kill activity of the streptogramin NXL 103 against Gram-positive and -negative bacteria.
Antimicrobial agents and chemotherapy 2011;55(4):1787-91.
2010: Klaudia Kosowska-Shick; Kathleen G Julian; Pamela McGhee; Peter C Appelbaum; Cynthia J Whitener
Molecular and epidemiologic characteristics of linezolid-resistant coagulase-negative staphylococci at a tertiary care hospital.
Diagnostic microbiology and infectious disease 2010;68(1):34-9.
2010: Glenn A Pankuch; Harald Seifert; Peter C Appelbaum
Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
Diagnostic microbiology and infectious disease 2010;67(2):191-7.
2010: Kim Credito; Klaudia Kosowska-Shick; Peter C Appelbaum
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Antimicrobial agents and chemotherapy 2010;54(6):2692-5.
2010: Klaudia Kosowska-Shick; Pamela McGhee; Peter C Appelbaum
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2010;54(5):1670-7.
2010: Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
Antimicrobial agents and chemotherapy 2010;54(5):2201-5.
2010: Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
Antimicrobial agents and chemotherapy 2010;54(5):2258-61.
2010: Kim Credito; Klaudia Kosowska-Shick; Pamela McGhee; Glenn A Pankuch; Peter C Appelbaum
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Antimicrobial agents and chemotherapy 2010;54(2):673-7.
2010: Pamela McGhee; Catherine Clark; Klaudia M Kosowska-Shick; Kensuke Nagai; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
Antimicrobial agents and chemotherapy 2010;54(1):230-8.
2009: Glenn A Pankuch; Peter C Appelbaum
Postantibiotic effect of ceftaroline against gram-positive organisms.
Antimicrobial agents and chemotherapy 2009;53(10):4537-9.
2009: Klaudia Kosowska-Shick; Catherine Clark; Glenn A Pankuch; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
Antimicrobial agents and chemotherapy 2009;53(10):4217-24.
2009: Catherine Clark; Klaudia Kosowska-Shick; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.
Antimicrobial agents and chemotherapy 2009;53(7):3118-21.
2009: Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Peter C Appelbaum
Comparative antipneumococcal activities of sulopenem and other drugs.
Antimicrobial agents and chemotherapy 2009;53(6):2239-47.
2009: Klaudia Kosowska-Shick; Pamela McGhee; Peter C Appelbaum
Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
Antimicrobial agents and chemotherapy 2009;53(5):2176-80.
2009: Lois M Ednie; Peter C Appelbaum
Antianaerobic activity of sulopenem compared to six other agents.
Antimicrobial agents and chemotherapy 2009;53(5):2163-70.
2009: Catherine Clark; Lois M Ednie; Gengrong Lin; Kathy Smith; Klaudia Kosowska-Shick; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Patrick Caspers; Bérangère Gaucher; Gürkan Mert; Stuart Shapiro; Peter C Appelbaum
Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
Antimicrobial agents and chemotherapy 2009;53(4):1353-61.
2009: Glenn A Pankuch; Peter C Appelbaum
Postantibiotic effects of telavancin against 16 gram-positive organisms.
Antimicrobial agents and chemotherapy 2009;53(3):1275-7.
2009: Glenn A Pankuch; Peter C Appelbaum
Postantibiotic effect of tigecycline against 14 gram-positive organisms.
Antimicrobial agents and chemotherapy 2009;53(2):782-4.
2009: Sachin S Bhagwat; Pamela McGhee; Klaudia Kosowska-Shick; Mahesh V Patel; Peter C Appelbaum
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
Antimicrobial agents and chemotherapy 2009;53(2):811-3.
2009: Kim Credito; Gengrong Lin; Laura Koeth; Michael A Sturgess; Peter C Appelbaum
Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.
Antimicrobial agents and chemotherapy 2009;53(2):814-7.
2008: Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.
Antimicrobial agents and chemotherapy 2008;52(12):4510-3.
2008: Masaaki Ikenaga; Klaudia Kosowska-Shick; Kenji Gotoh; Hidenobu Hidaka; Hiroyasu Koga; Kenji Masunaga; Kensuke Nagai; Naoki Tsumura; Peter C Appelbaum; Toyojiro Matsuishi
Genotypes of macrolide-resistant pneumococci from children in southwestern Japan: raised incidence of strains that have both erm(B) and mef(A) with serotype 6B clones.
Diagnostic microbiology and infectious disease 2008;62(1):16-22.
2008: Kathy Smith; Lois M Ednie; Peter C Appelbaum; Stephen Hawser; Sergio Lociuro
Antistreptococcal activity of AR-709 compared to that of other agents.
Antimicrobial agents and chemotherapy 2008;52(6):2279-82.
2008: Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois M Ednie; Peter C Appelbaum
In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.
Antimicrobial agents and chemotherapy 2008;52(2):748-52.
2008: Gengrong Lin; Peter C Appelbaum
Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
Diagnostic microbiology and infectious disease 2008;60(2):233-5.
2008: Artur J Sabat; Benedykt Wladyka; Klaudia Kosowska-Shick; Hajo Grundmann; Jan Maarten van Dijl; Julia Kowal; Peter C Appelbaum; Adam Dubin; Waleria Hryniewicz
Polymorphism, genetic exchange and intragenic recombination of the aureolysin gene among Staphylococcus aureus strains.
BMC microbiology 2008;8():129.
2008: Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
Antimicrobial agents and chemotherapy 2008;52(1):333-6.
2008: Catherine Clark; Kathy Smith; Lois M Ednie; Tatiana Bogdanovich; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 2008;52(1):77-84.
2008: Kim Credito; Lois M Ednie; Peter C Appelbaum
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
Antimicrobial agents and chemotherapy 2008;52(1):365-73.
2007: Catherine L Clark; Klaudia Kosowska-Shick; Lois M Ednie; Peter C Appelbaum
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Antimicrobial agents and chemotherapy 2007;51(11):4196-201.
2007: Tatiana Bogdanovich; Catherine Clark; Klaudia Kosowska-Shick; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
Antimicrobial agents and chemotherapy 2007;51(11):4191-5.
2007: Tatiana Bogdanovich; Neriman Aydin; Susana Chavez-Bueno; George McCracken; Bülent Bozdogan; Peter C Appelbaum
Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.
Diagnostic microbiology and infectious disease 2007;59(2):231-3.
2007: Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois M Ednie; Laura M Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
Antimicrobial agents and chemotherapy 2007;51(9):3445-8.
2007: Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
Diagnostic microbiology and infectious disease 2007;58(1):133-6.
2007: Kim Credito; Genrong Lin; Peter C Appelbaum
Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing.
Antimicrobial agents and chemotherapy 2007;51(4):1508-11.
2007: Kim Credito; Gengrong Lin; Peter C Appelbaum
Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
Antimicrobial agents and chemotherapy 2007;51(4):1504-7.
2007: Klaudia Kosowska-Shick; Kim Credito; Glenn A Pankuch; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Antimicrobial agents and chemotherapy 2007;51(2):770-3.
2006: Klaudia Kosowska-Shick; Kathy Smith; Tatiana Bogdanovich; Lois M Ednie; Ronald Jones; Peter C Appelbaum
Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
Antimicrobial agents and chemotherapy 2006;50(12):4191-4.
2006: Glenn A Pankuch; Peter C Appelbaum
Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms.
Antimicrobial agents and chemotherapy 2006;50(11):3956-8.
2006: Glenn A Pankuch; Dianne B Hoellman; André Bryskier; John Lowther; Peter C Appelbaum
Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae.
Antimicrobial agents and chemotherapy 2006;50(11):3914-6.
2006: Michael R Jacobs; Peter C Appelbaum
Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.
Expert opinion on pharmacotherapy 2006;7(14):1957-66.
2006: Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Activity of LBM415 compared to those of 11 other agents against Haemophilus species.
Antimicrobial agents and chemotherapy 2006;50(7):2323-9.
2006: Klaudia Kosowska-Shick; Kim Credito; Glenn A Pankuch; Gengrong Lin; Bülent Bozdogan; Pamela McGhee; Bonifacio Dewasse; Dong-Rack Choi; Jei Man Ryu; Peter C Appelbaum
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Antimicrobial agents and chemotherapy 2006;50(6):2064-71.
2006: Tatiana Bogdanovich; Catherine Clark; Lois M Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Antimicrobial agents and chemotherapy 2006;50(6):2050-7.
2006: Glenn A Pankuch; Gengrong Lin; Dianne B Hoellman; Caryn E Good; Michael R Jacobs; Peter C Appelbaum
Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.
Antimicrobial agents and chemotherapy 2006;50(5):1727-30.
2006: Glenn A Pankuch; Peter C Appelbaum
Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species.
Antimicrobial agents and chemotherapy 2006;50(3):1112-7.
2006: Tatiana Bogdanovich; Bülent Bozdogan; Peter C Appelbaum
Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae.
Antimicrobial agents and chemotherapy 2006;50(3):893-8.
2006: Peter C Appelbaum
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12 Suppl 1():16-23.
2006: Ahmet Yilmaz Coban; Bülent Bozdogan; Cigdem Cekic Cihan; Ebru Cetinkaya; Kemal Bilgin; Ozge Darka; Alper Akgunes; Belma Durupinar; Peter C Appelbaum
Two new colorimetric methods for early detection of vancomycin and oxacillin resistance in Staphylococcus aureus.
Journal of clinical microbiology 2006;44(2):580-2.
2006: Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Pamela McGhee; Bonifacio Dewasse; Tatiana Bogdanovich; Peter C Appelbaum
Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.
Antimicrobial agents and chemotherapy 2006;50(2):765-9.
2005: Glenn A Pankuch; Gengrong Lin; Peter C Appelbaum
Activity of five quinolones, three macrolides and telithromycin against 12 Haemophilus influenzae strains with different resistance phenotypes.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11(12):1040-4.
2005: Gengrong Lin; Kathy Smith; Lois M Ednie; Peter C Appelbaum
Antipneumococcal activity of dalbavancin compared to other agents.
Antimicrobial agents and chemotherapy 2005;49(12):5182-4.
2005: David Felmingham; Anthony R White; Michael R Jacobs; Peter C Appelbaum; James Poupard; Linda A Miller; Reuben N Grüneberg
The Alexander Project: the benefits from a decade of surveillance.
The Journal of antimicrobial chemotherapy 2005;56 Suppl 2():ii3-ii21.
2005: Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Antimicrobial agents and chemotherapy 2005;49(10):4210-9.
2005: Peter C Appelbaum; Michael R Jacobs
Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
Current opinion in microbiology 2005;8(5):510-7.
2005: Glenn A Pankuch; Peter C Appelbaum
Postantibiotic effect of DX-619 against 16 gram-positive organisms.
Antimicrobial agents and chemotherapy 2005;49(9):3963-5.
2005: Noël de Souza; Shrikant V Gupte; Prasad K Deshpande; Vijaya N Desai; Satish B Bhawsar; Ravindra Yeole; Milind C Shukla; Jacob Strahilevitz; David C Hooper; Bülent Bozdogan; Peter C Appelbaum; Michael R Jacobs; Nitin Shetty; Mahesh V Patel; Rasendrakumar Jha; Habil F Khorakiwala
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Journal of medicinal chemistry 2005;48(16):5232-42.
2005: Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Antimicrobial agents and chemotherapy 2005;49(8):3325-33.
2005: Natalia Malachowa; Artur Sabat; Marek Gniadkowski; Jolanta Krzyszton-Russjan; Joanna Empel; Jacek Miedzobrodzki; Klaudia Kosowska-Shick; Peter C Appelbaum; Waleria Hryniewicz
Comparison of multiple-locus variable-number tandem-repeat analysis with pulsed-field gel electrophoresis, spa typing, and multilocus sequence typing for clonal characterization of Staphylococcus aureus isolates.
Journal of clinical microbiology 2005;43(7):3095-100.
2005: Susana Chavez-Bueno; Bülent Bozdogan; Kathy Katz; Karen L Bowlware; Nancy Cushion; Dominick Cavuoti; Naveed Ahmad; George H McCracken; Peter C Appelbaum
Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas.
Antimicrobial agents and chemotherapy 2005;49(6):2283-8.
2005: Klaudia Kosowska; Dianne B Hoellman; Gengrong Lin; Catherine Clark; Kim Credito; Pamela McGhee; Bonifacio Dewasse; Bülent Bozdogan; Stuart Shapiro; Peter C Appelbaum
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
Antimicrobial agents and chemotherapy 2005;49(5):1932-42.
2005: Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Antimicrobial agents and chemotherapy 2005;49(2):770-2.
2005: Peter C Appelbaum; Glenn A Pankuch; Bülent Bozdogan; Gengrong Lin; Michael R Jacobs; Mahesh V Patel; S V Gupte; M A Jafri; Noël de Souza; Habil F Khorakiwala
Activity of the new quinolone WCK 771 against pneumococci.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11(1):9-14.
2004: Bülent Bozdogan; Lois M Ednie; Kim Credito; Klaudia Kosowska; Peter C Appelbaum
Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center.
Antimicrobial agents and chemotherapy 2004;48(12):4762-5.
2004: Mahesh V Patel; Noël de Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Antimicrobial agents and chemotherapy 2004;48(12):4754-61.
2004: Kim Credito; Peter C Appelbaum
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.
Antimicrobial agents and chemotherapy 2004;48(11):4430-4.
2004: Klaudia Kosowska; Kim Credito; Glenn A Pankuch; Dianne B Hoellman; Gengrong Lin; Catherine Clark; Bonifacio Dewasse; Pamela McGhee; Michael R Jacobs; Peter C Appelbaum
Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Antimicrobial agents and chemotherapy 2004;48(11):4113-9.
2004: Vlatka Matic; Klaudia Kosowska; Bülent Bozdogan; Linda M Kelly; Kathy Smith; Lois M Ednie; Gengrong Lin; Kim Credito; Catherine L Clark; Pamela McGhee; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Antimicrobial agents and chemotherapy 2004;48(11):4103-12.
2004: Dianne B Hoellman; Glenn A Pankuch; Peter C Appelbaum
Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
Antimicrobial agents and chemotherapy 2004;48(10):4037-9.
2004: Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Antimicrobial agents and chemotherapy 2004;48(10):4033-6.
2004: K Kosowska; Michael R Jacobs; Saralee Bajaksouzian; Laura M Koeth; Peter C Appelbaum
Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs.
Antimicrobial agents and chemotherapy 2004;48(10):4020-2.
2004: Bülent Bozdogan; Tatiana Bogdanovich; Klaudia Kosowska; Michael R Jacobs; Peter C Appelbaum
Macrolide resistance in Streptococcus pneumoniae: clonality and mechanisms of resistance in 24 countries.
Current drug targets. Infectious disorders 2004;4(3):169-76.
2004: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Mahesh V Patel; Shrikant V Gupte; Sachin S Bhagwat; Noël de Souza; Habil F Khorakiwala
In vitro activity of the new quinolone WCK 771 against staphylococci.
Antimicrobial agents and chemotherapy 2004;48(9):3338-42.
2004: Mihaela Peric; Michael R Jacobs; Peter C Appelbaum
Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.
Antimicrobial agents and chemotherapy 2004;48(8):3188-92.
2004: Mihaela Peric; Bülent Bozdogan; Chad Galderisi; Dan Krissinger; Terry Rager; Peter C Appelbaum
Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S.
The Journal of antimicrobial chemotherapy 2004;54(2):393-400.
2004: Peter C Appelbaum; S H Gillespie; C J Burley; G S Tillotson
Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
International journal of antimicrobial agents 2004;23(6):533-46.
2004: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Caryn E Good; Gengrong Lin; Glenn A Pankuch; Peter C Appelbaum
Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study.
Clinics in laboratory medicine 2004;24(2):503-30.
2004: Bülent Bozdogan; Peter C Appelbaum
Macrolide resistance in Streptococci and Haemophilus influenzae.
Clinics in laboratory medicine 2004;24(2):455-75.
2004: Michael R Jacobs; Jack B Anon; Peter C Appelbaum
Mechanisms of resistance among respiratory tract pathogens.
Clinics in laboratory medicine 2004;24(2):419-53.
2004: Peter C Appelbaum; Bülent Bozdogan
Vancomycin resistance in Staphylococcus aureus.
Clinics in laboratory medicine 2004;24(2):381-402.
2004: Laura M Koeth; Caryn E Good; Peter C Appelbaum; Ellie J C Goldstein; Arne C Rodloff; Marina C Claros; Luc Dubreuil
Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents.
The Journal of antimicrobial chemotherapy 2004;53(6):1039-44.
2004: Catherine Clark; Klaudia Kosowska; Bülent Bozdogan; Kim Credito; Bonifacio Dewasse; Pamela McGhee; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance in haemophilus influenzae by 4 quinolones and 5 beta-lactams.
Diagnostic microbiology and infectious disease 2004;49(1):31-6.
2004: Cynthia Whitener; Sarah Y Park; Frederick A Browne; Leslie J Parent; Kathleen G Julian; Bülent Bozdogan; Peter C Appelbaum; Jasmine Chaitram; Linda M Weigel; John A Jernigan; Linda McDougal; Fred C Tenover; Scott K Fridkin
Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(8):1049-55.
2004: Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura A Jevitt; Jean B Patel; Bülent Bozdogan
Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.
Antimicrobial agents and chemotherapy 2004;48(1):275-80.
2003: Frederick A Browne; Bülent Bozdogan; Catherine Clark; Linda M Kelly; Lois M Ednie; Klaudia Kosowska; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
Antimicrobial agents and chemotherapy 2003;47(12):3815-24.
2003: Vlatka Matic; Bülent Bozdogan; Michael R Jacobs; Kimiko Ubukata; Peter C Appelbaum
Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in beta-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae.
The Journal of antimicrobial chemotherapy 2003;52(6):1018-21.
2003: Bülent Bozdogan; Duygu Esel; Cynthia Whitener; Frederick A Browne; Peter C Appelbaum
Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.
The Journal of antimicrobial chemotherapy 2003;52(5):864-8.
2003: Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum
Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci.
The Journal of antimicrobial chemotherapy 2003;52(5):809-12.
2003: Summer R Youker; Robert J Andreozzi; Peter C Appelbaum; Kim Credito; Jeffrey J Miller
White piedra: further evidence of a synergistic infection.
Journal of the American Academy of Dermatology 2003;49(4):746-9.
2003: Glenn A Pankuch; Linda M Kelly; Gengrong Lin; André Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.
Antimicrobial agents and chemotherapy 2003;47(10):3270-4.
2003: Bülent Bozdogan; Peter C Appelbaum; Lois M Ednie; Ioanna N Grivea; George A Syrogiannopoulos
Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(9):966-9.
2003: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.
Antimicrobial agents and chemotherapy 2003;47(9):3012-4.
2003: George A Syrogiannopoulos; Ioanna N Grivea; Lois M Ednie; Bülent Bozdogan; George D Katopodis; Nicholas G Beratis; Todd A Davies; Peter C Appelbaum
Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A).
Antimicrobial agents and chemotherapy 2003;47(8):2699-702.
2003: Michael R Jacobs; David Felmingham; Peter C Appelbaum; Reuben N Grüneberg
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
The Journal of antimicrobial chemotherapy 2003;52(2):229-46.
2003: Bülent Bozdogan; Peter C Appelbaum; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Helena Hupkova; Michael R Jacobs; Jana Kolman; M Konkoly-Thege; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Jan Trupl; Pavla Urbaskova
Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):741-5.
2003: Bülent Bozdogan; Peter C Appelbaum; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Helena Hupkova; Michael R Jacobs; Jana Kolman; M Konkoly-Thege; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Jan Trupl; Pavla Urbaskova
Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):653-61.
2003: Kim Credito; Michael R Jacobs; Peter C Appelbaum
In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-kill.
The Journal of antimicrobial chemotherapy 2003;51(6):1437-9.
2003: Kim Credito; Michael R Jacobs; Peter C Appelbaum
Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.
Antimicrobial agents and chemotherapy 2003;47(4):1399-402.
2003: Dianne B Hoellman; Gengrong Lin; Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
Antimicrobial agents and chemotherapy 2003;47(3):1148-50.
2003: Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
Antimicrobial agents and chemotherapy 2003;47(3):1143-7.
2003: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.
Antimicrobial agents and chemotherapy 2003;47(3):1140-2.
2003: Mihaela Peric; Bülent Bozdogan; Michael R Jacobs; Peter C Appelbaum
Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.
Antimicrobial agents and chemotherapy 2003;47(3):1017-22.
2003: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.
The Journal of antimicrobial chemotherapy 2003;51(2):443-6.
2003: Mihaela Peric; Frederick A Browne; Michael R Jacobs; Peter C Appelbaum
Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Clinical therapeutics 2003;25(1):169-77.
2003: Bülent Bozdogan; Catherine Clark; André Bryskier; Michael R Jacobs; Peter C Appelbaum
Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae.
Antimicrobial agents and chemotherapy 2003;47(1):405-7.
2002: Dianne B Hoellman; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8(12):814-22.
2002: Michael R Jacobs; Laura M Koeth; Peter C Appelbaum
Use of appropriate breakpoints in antimicrobial surveillance studies.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;35(11):1446-8; author reply 1448-9.
2002: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Gengrong Lin; David Felmingham; Christine Dencer; Laura M Koeth; Mendel E Singer; Caryn E Good
Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.
Journal of clinical microbiology 2002;40(9):3269-76.
2002: Catherine Clark; Bülent Bozdogan; Mihaela Peric; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
Antimicrobial agents and chemotherapy 2002;46(9):2956-62.
2002: Elizabeth Palavecino; I Riedel; C Duran; Saralee Bajaksouzian; Moses L Joloba; T Davies; Peter C Appelbaum; Michael R Jacobs
Macrolide resistance phenotypes in Streptococcus pneumoniae in Santiago, Chile.
International journal of antimicrobial agents 2002;20(2):108-12.
2002: Frederick A Browne; Cathy Clark; Bülent Bozdogan; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
International journal of antimicrobial agents 2002;20(2):93-9.
2002: Glenn A Pankuch; Bülent Bozdogan; Kensuke Nagai; Arjana Tambić-Andrasević; Slavko Schoenwald; Tera Tambić; Smilja Kalenić; Sanja Plesko; Nastja K Tepes; Zdenka Kotarski; Marina Payerl-Pal; Peter C Appelbaum
Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia.
Antimicrobial agents and chemotherapy 2002;46(8):2671-5.
2002: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
The Journal of antimicrobial chemotherapy 2002;50(1):101-5.
2002: Catherine L Clark; Kensuke Nagai; Bonifacio Dewasse; Glenn A Pankuch; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of cefditoren against respiratory pathogens.
The Journal of antimicrobial chemotherapy 2002;50(1):33-41.
2002: Peter C Appelbaum
Resistance among Streptococcus pneumoniae: Implications for drug selection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(12):1613-20.
2002: Catherine L Clark; Kensuke Nagai; Todd A Davies; Bülent Bozdogan; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8(6):373-80.
2002: Brigitte Malbruny; Kensuke Nagai; Maëlle Coquemont; Bülent Bozdogan; Arjana Tambic Andrasevic; Helena Hupkova; Roland Leclercq; Peter C Appelbaum
Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations.
The Journal of antimicrobial chemotherapy 2002;49(6):935-9.
2002: Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci.
Antimicrobial agents and chemotherapy 2002;46(5):1273-80.
2002: Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.
Antimicrobial agents and chemotherapy 2002;46(2):546-9.
2002: Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.
Antimicrobial agents and chemotherapy 2002;46(2):371-7.
2002: Laura M Koeth; Michael R Jacobs; Saralee Bajaksouzian; Anne Zilles; Gengrong Lin; Peter C Appelbaum
Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
International journal of antimicrobial agents 2002;19(1):33-7.
2002: Glenn A Pankuch; Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of BMS 284756 compared to those of six other agents.
Antimicrobial agents and chemotherapy 2002;46(1):251-4.
2002: Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Antimicrobial agents and chemotherapy 2002;46(1):220-4.
2002: Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2002;46(1):125-31.
2002: Glenn A Pankuch; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.
Antimicrobial agents and chemotherapy 2002;46(1):42-6.
2001: K Nagai; Y Shibasaki; K Hasegawa; Todd A Davies; Michael R Jacobs; K Ubukata; Peter C Appelbaum
Evaluation of PCR primers to screen for Streptococcus pneumoniae isolates and beta-lactam resistance, and to detect common macrolide resistance determinants.
The Journal of antimicrobial chemotherapy 2001;48(6):915-8.
2001: K Nagai; Todd A Davies; Lois M Ednie; André Bryskier; E Palavecino; Michael R Jacobs; Peter C Appelbaum
Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
Antimicrobial agents and chemotherapy 2001;45(11):3242-5.
2001: Moses L Joloba; Anne Windau; Saralee Bajaksouzian; Peter C Appelbaum; W P Hausdorff; Michael R Jacobs
Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(9):1489-94.
2001: K Nagai; Todd A Davies; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2001;48(3):365-74.
2001: Dianne B Hoellman; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Comparative antianaerobic activity of BMS 284756.
Antimicrobial agents and chemotherapy 2001;45(2):589-92.
2001: George A Syrogiannopoulos; Ioanna N Grivea; A Tait-Kamradt; George D Katopodis; Nicholas G Beratis; Joyce Sutcliffe; Peter C Appelbaum; Todd A Davies
Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece.
Antimicrobial agents and chemotherapy 2001;45(1):342-4.
2001: Kim Credito; Gengrong Lin; Glenn A Pankuch; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.
Antimicrobial agents and chemotherapy 2001;45(1):67-72.
2000: Peter C Appelbaum
Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
Postgraduate medicine 2000;108(7 Suppl Contemporaty):5-16.
2000: K Nagai; Todd A Davies; Bonifacio Dewasse; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2000;46(6):909-15.
2000: A Tait-Kamradt; T Davies; Peter C Appelbaum; F Depardieu; P Courvalin; J Petitpas; L Wondrack; A Walker; M R Jacobs; Joyce Sutcliffe
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.
Antimicrobial agents and chemotherapy 2000;44(12):3395-401.
2000: Kim Credito; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole.
Diagnostic microbiology and infectious disease 2000;38(3):181-3.
2000: George A Syrogiannopoulos; Francesco Ronchetti; R Dagan; Ioanna N Grivea; Maria Paola Ronchetti; N Porat; Todd A Davies; Roberto Ronchetti; Peter C Appelbaum; MR Jacobs
Mediterranean clone of penicillin-susceptible, multidrug-resistant serotype 6B Streptococcus pneumoniae in Greece, Italy and Israel.
International journal of antimicrobial agents 2000;16(3):219-24.
2000: George A Syrogiannopoulos; Ioanna N Grivea; Todd A Davies; George D Katopodis; Peter C Appelbaum; Nicholas G Beratis
Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(4):887-93.
2000: K Nagai; Todd A Davies; Glenn A Pankuch; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2000;44(10):2740-6.
2000: Peter C Appelbaum; P A Hunter
The fluoroquinolone antibacterials: past, present and future perspectives.
International journal of antimicrobial agents 2000;16(1):5-15.
2000: Michael R Jacobs; Peter C Appelbaum
Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries. Laser Study Group.
International journal of antimicrobial agents 2000;16(1):17-24.
2000: A Tait-Kamradt; T Davies; Melissa Cronan; M R Jacobs; Peter C Appelbaum; Joyce Sutcliffe
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.
Antimicrobial agents and chemotherapy 2000;44(8):2118-25.
2000: Catherine L Clark; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Activity of trovafloxacin, alone and in combination with other agents, against Enterobacteriaceae by time-kill analysis.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2000;19(7):565-7.
2000: Todd A Davies; Lois M Ednie; D M Hoellman; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of ABT-773 compared to those of 10 other agents.
Antimicrobial agents and chemotherapy 2000;44(7):1894-9.
2000: Lois M Ednie; Kim Credito; M Khantipong; Michael R Jacobs; Peter C Appelbaum
Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
The Journal of antimicrobial chemotherapy 2000;45(5):633-8.
2000: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods.
The Journal of antimicrobial chemotherapy 2000;45(4):525-8.
2000: Todd A Davies; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.
Journal of clinical microbiology 2000;38(4):1444-8.
2000: Dianne B Hoellman; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 2000;44(4):1085-8.
2000: Todd A Davies; Linda M Kelly; Dianne B Hoellman; Lois M Ednie; Catherine L Clark; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
Antimicrobial agents and chemotherapy 2000;44(3):633-9.
2000: Todd A Davies; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2000;44(2):414-7.
2000: Todd A Davies; Linda M Kelly; Glenn A Pankuch; Kim Credito; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
Antimicrobial agents and chemotherapy 2000;44(2):304-10.
2000: S K Spangler; S Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.
Antimicrobial agents and chemotherapy 2000;44(1):186-9.
1999: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.
Antimicrobial agents and chemotherapy 1999;43(10):2574-5.
1999: Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae.
Journal of clinical microbiology 1999;37(10):3296-9.
1999: Glenn A Pankuch; Dianne B Hoellman; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time-kill kinetics.
The Journal of antimicrobial chemotherapy 1999;44(3):381-4.
1999: C L Clark; Michael R Jacobs; Peter C Appelbaum
Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
Antimicrobial agents and chemotherapy 1999;43(9):2295-8.
1999: Kim Credito; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Antimicrobial agents and chemotherapy 1999;43(8):2027-31.
1999: Michael R Jacobs; Saralee Bajaksouzian; A Zilles; Gengrong Lin; Glenn A Pankuch; Peter C Appelbaum
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.
Antimicrobial agents and chemotherapy 1999;43(8):1901-8.
1999: Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 1999;43(5):707-9.
1999: Dianne B Hoellman; Gengrong Lin; Michael R Jacobs; Peter C Appelbaum
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
The Journal of antimicrobial chemotherapy 1999;43(5):645-9.
1999: T Davies; Richard Goering; Marguerite Lovgren; James A Talbot; Michael R Jacobs; Peter C Appelbaum
Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America.
Diagnostic microbiology and infectious disease 1999;34(1):7-12.
1999: Todd A Davies; Glenn A Pankuch; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 1999;43(5):1177-82.
1999: Peter C Appelbaum
Quinolone activity against anaerobes.
Drugs 1999;58 Suppl 2():60-4.
1999: Dianne B Hoellman; Gengrong Lin; Michael R Jacobs; Peter C Appelbaum
Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis.
Antimicrobial agents and chemotherapy 1999;43(1):166-8.
1998: Catherine L Clark; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies.
Journal of clinical microbiology 1998;36(12):3579-84.
1998: Glenn A Pankuch; Dianne B Hoellman; G Lin; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.
Antimicrobial agents and chemotherapy 1998;42(11):3032-4.
1998: Glenn A Pankuch; S A Jueneman; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 1998;42(11):2914-8.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Antimicrobial agents and chemotherapy 1998;42(9):2459-62.
1998: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.
Antimicrobial agents and chemotherapy 1998;42(8):2002-5.
1998: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.
Antimicrobial agents and chemotherapy 1998;42(6):1503-5.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
Antimicrobial agents and chemotherapy 1998;42(5):1269-73.
1998: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology.
Antimicrobial agents and chemotherapy 1998;42(5):1263-5.
1998: SK Spangler; G Lin; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
Antimicrobial agents and chemotherapy 1998;42(5):1253-5.
1998: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Antimicrobial agents and chemotherapy 1998;42(4):953-5.
1998: Dianne B Hoellman; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
Antimicrobial agents and chemotherapy 1998;42(4):857-61.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of erythromycin, azithromycin and clarithromycin: effect of pH adjustment of media to compensate for pH shift caused by incubation in CO2.
The Journal of antimicrobial chemotherapy 1998;41(3):387-9.
1998: Glenn A Pankuch; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
Antimicrobial agents and chemotherapy 1998;42(3):624-30.
1998: Michael R Jacobs; R Dagan; Peter C Appelbaum; D J Burch
Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media.
Antimicrobial agents and chemotherapy 1998;42(3):589-95.
1998: Dianne B Hoellman; SK Spangler; Michael R Jacobs; Peter C Appelbaum
In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
Antimicrobial agents and chemotherapy 1998;42(3):495-501.
1998: MA Visalli; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Synergistic activity of trovafloxacin with other agents against gram-positive and -negative organisms.
Diagnostic microbiology and infectious disease 1998;30(1):61-4.
1998: Michael R Jacobs; Saralee Bajaksouzian; E L Palavecino-Fasola; H M Holoszyc; Peter C Appelbaum
Determination of penicillin MICs for Streptococcus pneumoniae by using a two- or three-disk diffusion procedure.
Journal of clinical microbiology 1998;36(1):179-83.
1997: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
Antimicrobial agents and chemotherapy 1997;41(12):2786-9.
1997: S K Spangler; Gengrong Lin; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1997;41(10):2173-6.
1997: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).
Antimicrobial agents and chemotherapy 1997;41(9):2019-22.
1997: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Antimicrobial agents and chemotherapy 1997;41(9):1867-70.
1997: George A Syrogiannopoulos; Ioanna N Grivea; Nicholas G Beratis; A E Spiliopoulou; E L Fasola; Saralee Bajaksouzian; Peter C Appelbaum; MR Jacobs
Resistance patterns of streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(2):188-94.
1997: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Diagnostic microbiology and infectious disease 1997;28(3):131-7.
1997: MA Visalli; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Antimicrobial agents and chemotherapy 1997;41(7):1475-81.
1997: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
The Journal of antimicrobial chemotherapy 1997;39 Suppl B():23-7.
1997: Saralee Bajaksouzian; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.
Antimicrobial agents and chemotherapy 1997;41(5):1073-6.
1997: Lois M Ednie; SK Spangler; Michael R Jacobs; Peter C Appelbaum
Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.
Antimicrobial agents and chemotherapy 1997;41(5):1037-41.
1997: Lois M Ednie; SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.
Antimicrobial agents and chemotherapy 1997;41(5):1033-6.
1997: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.
Antimicrobial agents and chemotherapy 1997;41(4):847-9.
1997: MA Visalli; Michael R Jacobs; T D Moore; F A Renzi; Peter C Appelbaum
Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.
Antimicrobial agents and chemotherapy 1997;41(4):767-70.
1997: S K Spangler; Michael R Jacobs; Peter C Appelbaum
Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams.
The Journal of antimicrobial chemotherapy 1997;39(2):141-8.
1997: SK Spangler; Michael R Jacobs; Peter C Appelbaum
MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.
Antimicrobial agents and chemotherapy 1997;41(1):148-55.
1997: E L Fasola; Saralee Bajaksouzian; Peter C Appelbaum; Michael R Jacobs
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.
Antimicrobial agents and chemotherapy 1997;41(1):129-34.
1996: E Fasola; SK Spangler; Lois M Ednie; Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(11):2661-3.
1996: Peter C Appelbaum; C Gladkova; Waleria Hryniewicz; B Kojouharov; D Kotulova; F Mihalcu; J Schindler; L Setchanova; N Semina; J Trupl; S Tyski; P Urbaskova; Michael R Jacobs
Carriage of antibiotic-resistant Streptococcus pneumoniae by children in eastern and central Europe--a multicenter study with use of standardized methods.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(4):712-7.
1996: Peter C Appelbaum
Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae.
The Pediatric infectious disease journal 1996;15(10):932-4.
1996: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(9):2071-4.
1996: Saralee Bajaksouzian; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods.
Antimicrobial agents and chemotherapy 1996;40(9):1973-6.
1996: Lois M Ednie; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(8):1950-2.
1996: Glenn A Pankuch; C Lichtenberger; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.
Antimicrobial agents and chemotherapy 1996;40(7):1653-6.
1996: T T Kitch; Michael R Jacobs; M R McGinnis; Peter C Appelbaum
Ability of RapID Yeast Plus System to identify 304 clinically significant yeasts within 5 hours.
Journal of clinical microbiology 1996;34(5):1069-71.
1996: SK Spangler; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.
Antimicrobial agents and chemotherapy 1996;40(3):772-5.
1996: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(2):481-4.
1996: MA Visalli; Michael R Jacobs; Peter C Appelbaum
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(2):362-6.
1996: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
The Journal of antimicrobial chemotherapy 1996;37(1):77-84.
1995: Glenn A Pankuch; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1995;39(7):1499-504.
1995: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies.
Journal of clinical microbiology 1995;33(5):1366-7.
1995: Peter C Appelbaum
Quinolone activity against anaerobes: microbiological aspects.
Drugs 1995;49 Suppl 2():76-80.
1995: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci.
Drugs 1995;49 Suppl 2():235-7.
1994: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Antimicrobial agents and chemotherapy 1994;38(12):2905-7.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
Antimicrobial agents and chemotherapy 1994;38(12):2902-4.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Antimicrobial agents and chemotherapy 1994;38(11):2599-604.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Antimicrobial agents and chemotherapy 1994;38(10):2471-6.
1994: Glenn A Pankuch; Michael R Jacobs; S F Rittenhouse; Peter C Appelbaum
Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.
Antimicrobial agents and chemotherapy 1994;38(10):2317-22.
1994: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Antimicrobial agents and chemotherapy 1994;38(9):2065-72.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.
Antimicrobial agents and chemotherapy 1994;38(4):898-900.
1994: T T Kitch; Michael R Jacobs; Peter C Appelbaum
Evaluation of RapID onE system for identification of 379 strains in the family Enterobacteriaceae and oxidase-negative, gram-negative nonfermenters.
Journal of clinical microbiology 1994;32(4):931-4.
1994: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
Antimicrobial agents and chemotherapy 1994;38(2):369-70.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.
Antimicrobial agents and chemotherapy 1994;38(2):211-6.
1994: Peter C Appelbaum; SK Spangler; Glenn A Pankuch; A Philippon; Michael R Jacobs; R Shiman; E J Goldstein; D M Citron
Characterization of a beta-lactamase from Clostridium clostridioforme.
The Journal of antimicrobial chemotherapy 1994;33(1):33-40.
1994: Peter C Appelbaum; SK Spangler; M Cohen; Michael R Jacobs
Comparison of the E-test and conventional agar dilution methods for susceptibility testing of gram-negative anaerobic rods.
Diagnostic microbiology and infectious disease 1994;18(1):25-30.
1993: S K Spangler; Michael R Jacobs; Peter C Appelbaum
Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(12):965-7.
1993: Peter C Appelbaum; SK Spangler; Michael R Jacobs
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
The Journal of antimicrobial chemotherapy 1993;32(2):223-31.
1993: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Antimicrobial agents and chemotherapy 1993;37(8):1649-54.
1993: SK Spangler; Michael R Jacobs; Glenn A Pankuch; Peter C Appelbaum
Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
The Journal of antimicrobial chemotherapy 1993;31(2):273-80.
1993: SK Spangler; Peter C Appelbaum
Oxyrase, a method which avoids CO2 in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by CO2.
Journal of clinical microbiology 1993;31(2):460-2.
1993: Peter C Appelbaum
Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
The Journal of antimicrobial chemotherapy 1993;31 Suppl A():29-38.
1992: Michael R Jacobs; SK Spangler; Peter C Appelbaum
beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(11):1081-93.
1992: Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum; A Bolmström
Evaluation of the E-Test for susceptibility testing of pneumococci.
Diagnostic microbiology and infectious disease 1992;15(5):473-8.
1992: Peter C Appelbaum
Antimicrobial resistance in Streptococcus pneumoniae: an overview.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1992;15(1):77-83.
1992: T T Kitch; Michael R Jacobs; Peter C Appelbaum
Evaluation of the 4-hour RapID NF Plus method for identification of 345 gram-negative nonfermentative rods.
Journal of clinical microbiology 1992;30(5):1267-70.
1992: Peter C Appelbaum; SK Spangler; R Shiman; Michael R Jacobs
Susceptibilities of 540 anaerobic gram-negative bacilli to amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanate, temafloxacin, and clindamycin.
Antimicrobial agents and chemotherapy 1992;36(5):1140-3.
1992: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Antimicrobial agents and chemotherapy 1992;36(4):856-9.
1991: Peter C Appelbaum; SK Spangler; Michael R Jacobs
Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
Antimicrobial agents and chemotherapy 1991;35(6):1214-8.
1990: Michael R Jacobs; SK Spangler; Peter C Appelbaum
Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
The Journal of antimicrobial chemotherapy 1990;26(3):361-70.
1990: Peter C Appelbaum; S K Spangler; Michael R Jacobs
Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
Antimicrobial agents and chemotherapy 1990;34(8):1546-50.
1990: Michael R Jacobs; SK Spangler; Peter C Appelbaum
Susceptibility of Bacteroides non-fragilis and fusobacteria to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(6):417-21.
1990: Peter C Appelbaum; SK Spangler; Michael R Jacobs
Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(1):47-50.
1989: T T Kitch; Peter C Appelbaum
Accuracy and reproducibility of the 4-hour ATB 32A method for anaerobe identification.
Journal of clinical microbiology 1989;27(11):2509-13.
1989: Michael R Jacobs; Stephen C. Aronoff; Peter C Appelbaum; S Yamabe
In vitro activity of YTR 830.
Journal of chemotherapy (Florence, Italy) 1989;1(3):151-4.
1989: Peter C Appelbaum; SK Spangler; E Crotty; Michael R Jacobs
Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.
The Journal of antimicrobial chemotherapy 1989;23(4):509-16.
1988: N Ahsan; R L Conter; Peter C Appelbaum
Postoperative wound infection associated with Vibrio parahaemolyticus in a patient without exposure to seawater.
Journal of clinical microbiology 1988;26(6):1214-5.
1988: Peter C Appelbaum; SK Spangler; M Strauss
Reduction of oral flora with ciprofloxacin in healthy volunteers.
The Journal of antimicrobial chemotherapy 1988;21(2):243-9.
1988: Peter C Appelbaum; SK Spangler; R Crist; A E Crist
Survival of bacteria in Difco CultureSwab and Marion Culturette II transport systems.
Journal of clinical microbiology 1988;26(1):136-8.
1988: Peter C Appelbaum; SK Spangler; T Tamarree
Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.
Chemotherapy 1988;34(1):40-5.
1987: Peter C Appelbaum
World-wide development of antibiotic resistance in pneumococci.
European journal of clinical microbiology 1987;6(4):367-77.